journal
https://read.qxmd.com/read/38409748/antimicrobial-dosing-recommendations-during-continuous-renal-replacement-therapy-different-databases-different-doses
#21
JOURNAL ARTICLE
Aysel Pehlivanli, Tuğba Yanik Yalçin, Fatma İrem Yeşiler, Helin Şahintürk, Özlem Kurt Azap, Pınar Zeyneloğlu, Bilgen Başgut
Meticulous antimicrobial management is essential among critically ill patients with acute kidney injury, particularly if renal replacement therapy is needed. Many factors affect drug removal in patients undergoing continuous renal replacement therapy CRRT. In this study, we aimed to compare current databases that are frequently used to adjust CRRT dosages of antimicrobial drugs with the gold standard. The dosage recommendations from various databases for antimicrobial drugs eliminated by CRRT were investigated...
February 26, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38372170/amikacin-treatment-in-urinary-tract-infection-patients-evaluating-the-risk-of-acute-kidney-injury-a-retrospective-cohort-study
#22
JOURNAL ARTICLE
Avner Dagan, Danny Epstein, Ami Neuberger, Jonathan Isenberg
The rise in ESBL-producing and carbapenem-resistant Gram-negative bacterial infections is alarming. Aminoglycosides remain attractive for treating urinary tract infections (UTIs). However, aminoglycosides-associated acute kidney injury (AKI) raises concerns, especially in patients with underlying renal impairment. We conducted a retrospective cohort study to evaluate the risk of AKI in patients with UTI empirically treated with amikacin. Among 395 patients (median age 41.9 years [IQR 28.3-67.1], 342 [86...
February 19, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38351652/prognostic-implications-of-response-to-neoadjuvant-chemotherapy-in-breast-cancer-subtypes
#23
JOURNAL ARTICLE
Anil Yıldiz, Ahmet Bilici, Ozgur Acikgoz, Jamshid Hamdard, Pelin Basim, Tansel Cakir, Asli Cakir, Omer Fatih Olmez, Cem Gezen, Ozcan Yildiz
The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to 2019, a total of 139 patients who were histologically confirmed to have breast cancer, underwent NAC, and subsequently received breast and axillary surgery, were retrospectively included in this study. The rates of pathological complete response (pCR) to NAC were significantly higher for HER2-positive and triple-negative subtypes than for luminal A and HER2-negative subtypes ( p  = 0...
February 13, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38351629/evaluation-of-in%C3%A2-vitro-activity-of-ceftaroline-ceftobiprole-and-their-combination-with-trimethoprim-sulfamethoxazole-against-mrsa-isolates-a-two-center-study
#24
JOURNAL ARTICLE
Hasan Cenk Mirza, Özlem Öğüç Şanlı
There is an increasing need for new synergistic antimicrobial combinations against multidrug-resistant bacteria. Our objective was to evaluate the activity of ceftaroline, ceftobiprole and their combination with trimethoprim/sulfamethoxazole against methicillin-resistant Staphylococcus aureus (MRSA) isolates recovered at two centers in Turkey. Activities of ceftaroline and ceftobiprole were tested against 100 MRSA isolates using gradient diffusion method. Activities of ceftaroline and ceftobiprole in combination with trimethoprim/sulfamethoxazole against 20 selected isolates (including all isolates that were non-susceptible to ceftaroline or ceftobiprole, and randomly selected isolates) were investigated using MIC:MIC ratio method...
February 13, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38339845/-in-vitro-killing-of-drug-susceptible-and-multidrug-resistant-bacteria-by-amikacin-considering-pulmonary-drug-concentrations-based-on-an-inhaled-formulation
#25
JOURNAL ARTICLE
Joseph M Blondeau, Leah D Blondeau, Shantelle D Fitch
Nosocomial infections with drug resistant bacteria impact morbidity and mortality, length of therapy and stay and the overall cost of treatment. Key pathogens with ventilator associated pneumonia may be drug-susceptible or multi-drug resistant and inhaled amikacin has been investigated as an adjunctive therapy option. High pulmonary drug concentrations (epithelial lining fluid [ELF]) along with minimal systemic toxicity is seen as an advantage to inhaled formulations. In vitro killing of bacteria using clinically relevant drug concentrations provide insight on bug-drug interactions...
February 10, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38616651/correction
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38481380/comparative-effectiveness-of-chemotherapy-in-different-histological-types-of-pancreatic-cancer-a-psm-based-study-using-the-seer-database
#27
JOURNAL ARTICLE
Canhua Luo, Linfeng Fan, Weijian Lun, Miaomiao Ma, Leshi Liang, Changhui Yu
This study aimed to compare the effectiveness of chemotherapy in different histological types of pancreatic cancer using data collected from the Surveillance, Epidemiology, and End Results (SEER) database. Patients who were diagnosed with pancreatic cancer between 2004 and 2015 were selected from the SEER database. Propensity score matching (PSM) was employed to minimize the selection bias. The Kaplan-Meier survival curves and the log-rank test were utilized to compare the overall survival (OS) and cancer-specific survival (CSS) among different groups...
April 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38303601/clinical-benefit-of-anti-pd-1-pd-l1-plus-chemotherapy-in-first-line-treatment-for-patients-over-the-age-of-65-or-75-with-metastatic-non-small-cell-lung-cancer-nsclc
#28
REVIEW
Thierry Landre, Christos Chouaïd, Nassyma Sadaoui, Djamila Bouharati, Chérifa Taleb
Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC. However, the clinical benefit of this combination in older patients is controversial. We performed a meta-analysis of phase III randomized trials that compared PD-1/PD-L1 inhibitor plus CT with CT alone in first line of treatment for older patients with advanced NSCLC. Subgroups of patients over 65 and over 75 were analyzed. The outcomes included overall survival (OS) and progression-free survival (PFS)...
February 1, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38263773/emerging-roles-of-ncrnas-regulating-abcc1-on-chemotherapy-resistance-of-cancer-a-review
#29
REVIEW
Feng Zhang, Xiaoyong Lei, Xiaoyan Yang
In the process of chemotherapy, drug resistance of cancer cells is a common and difficult problem of chemotherapy failure, and it is also the main cause of cancer recurrence and metastasis. Non-coding RNAs (ncRNAs) refer to the RNA that does not encode proteins, including microRNA (miRNA), long non-coding RNA (lncRNA) and circularRNA (circRNA), etc. NcRNAs are involved in a series of important life processes and further regulate the expression of ABCC1 by directly or indirectly up-regulating or down-regulating the expression of targeted mRNAs, making cancer cells more susceptible to drug resistance...
February 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38291982/self-assembled-redox-responsive-brd4-sirna-nanoparticles-fomulation-and-its-in%C3%A2-vitro-delivery-in-gastric-cancer-cells
#30
JOURNAL ARTICLE
Mengying Zhang, Zhonghua An, Yiming Jiang, Meijiao Wei, Xiangbo Li, Yifan Wang, Hongbo Wang, Yanling Gong
With the development of newer biomarkers in the diagnosis of gastric cancer (GC), therapeutic targets are emerging and molecular-targeted therapy is in progress RNA interference has emerged as a promising method of gene targeting therapy. However, naked small interfering RNA (siRNA) is unstable and susceptible to degradation, so employing vectors for siRNA delivery is the focus of our research. Therefore, we developed LMWP modified PEG-SS-PEI to deliver siRNA targeting BRD4 (L-NPs/siBRD4) for GC therapy. L-NPs/siBRD4 were prepared by electrostatic interaction and characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM)...
January 31, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38288996/pharmacokinetic-parameters-of-caz-avi-in-the-normal-lung-and-in-models-of-pneumonia-lessons-for-treatment-optimization-in-critical-care
#31
REVIEW
Sabiha Gul, Raffaella Gallo, Lorenzo Bertolino, Fabian Patauner, Salvatore Buono, Rosanna De Rosa, Clelia Esposito, Nicola Galdieri, Arta Karruli, Domenico Iossa, Eugenio Piscitelli, Roberto Andini, Antonio Corcione, Emanuele Durante-Mangoni
The spread of multidrug-resistant Gram-negative bacterial infections is a significant issue for worldwide public health. Gram-negative organisms regularly develop resistance to antibiotics, especially to β-lactam antimicrobials, which can drastically restrict the number of therapies. A third-generation cephalosporin and the non-β-lactam β-lactamase inhibitor avibactam, which exhibits broad-spectrum β-lactamase inhibition in vitro , are combined to form ceftazidime-avibactam (CAZ-AVI)...
January 30, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38288951/antihyperlipidemic-drug-rosuvastatin-suppressed-tumor-progression-and-potentiated-chemosensitivity-by-downregulating-ccna2-in-lung-adenocarcinoma
#32
JOURNAL ARTICLE
Xiang-Di Tan, Cui-Fang Luo, Si-Yu Liang
Rosuvastatin (RSV) is widely used to treat hyperlipidemia and hypercholesterolemia and is recommended for the primary and secondary prevention of cardiovascular diseases (CVD). In this study, we aimed to explore its action and mechanism in lung adenocarcinoma (LUAD) therapy. Lewis and CMT64 cell-based murine subcutaneous LUAD models were employed to explore the effects of RSV monotherapy combined with cisplatin and gemcitabine. Human lung fibroblasts and human LUAD cell lines were used to assess the effects of RSV on normal and LUAD cells...
January 30, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38263804/the-prognostic-factors-in-patients-with-advanced-hepatocellular-carcinoma-impact-of-treatment-sequencing
#33
JOURNAL ARTICLE
Osman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, Didem Tastekin, Senem Karabulut, Abidin Gündogdu, Nadiye Sever, Murat Ayhan, Abdussamed Çelebi, Nargiz Majidova, Alper Yaşar, Yeşim Ağyol, Pınar Erel, Erkam Kocaaslan, Ali Kaan Güren, Rukiye Arıkan, Selver Isık, Ozlem Ercelep, Sema Sezgin Goksu, Celal Alandag, İrem Bilgetekin, Burcu Caner, Ahmet Bilge Sahin, Ahmet Gulmez, Baran Akagunduz, Fatih Kose, Muhammet Ali Kaplan, Ender Dogan, Teoman Sakalar, Deniz Can Guven, Mustafa Gurbuz, Yakup Ergun, Mustafa Karaagac, Sema Turker, Ozlem Ozkul, Birol Yıldız, Süleyman Sahin, Atike Gokcen Demiray, Murat Sari, Bülent Erdogan, İlhan Hacıbekiroglu, Ömür Berna Çakmak Öksüzoğlu, Saadettin Kilickap, Ahmet Bilici, İbrahim Vedat Bayoglu, Sernaz Topaloglu, İrfan Cicin
The prognosis of patients with advanced HCC can vary widely depending on factors such as the stage of the cancer, the patient's overall health, and treatment regimens. This study aimed to investigate survival outcomes and associated factors in patients with hepatocellular carcinoma (HCC). In this retrospective study, data from 23 medical oncology clinics were analyzed. Progression-free survival (PFS) and overall survival (OS) values were estimated using the Kaplan-Meier method. Prognostic factors associated with survival which were identified in univariate analysis were subsequently evaluated in a multivariate Cox-regression survival analysis was conducted using the backward stepwise (Conditional LR) method to determine the independent predictors of PFS and OS...
January 23, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38250790/timing-of-chemotherapy-after-diagnosis-of-small-cell-lung-cancer
#34
JOURNAL ARTICLE
Faruk Tas, Akin Ozturk, Kayhan Erturk
Systemic chemotherapy is the backbone of therapeutic management in small cell lung cancer (SCLC) and delay of treatment may lead to adverse patient outcomes. This study was conducted to determine the time elapsed between pathological diagnosis and initiation of chemotherapy in SCLC patients and to evaluate its clinical significance. A total of 323 pathologically confirmed SCLC patients were enrolled in the study and analyzed retrospectively. The median value of the patients' time to treatment was used as the cut-off value in distinguishing between early and late chemotherapy...
January 22, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38240051/factors-associated-with-immune-related-thyroid-dysfunction-induced-by-pd-1-pd-l1-inhibitors-in-cancer-patients-an-observational-study
#35
JOURNAL ARTICLE
Xiao-Chen Wei, Yuan-Yuan Guo, Yi Zhang, Yi-Shan Bu, Feng-Ying Zhang
This study aimed to identify the potential factors associated with immune thyroid dysfunction caused by programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in cancer patients. We conducted a retrospective study of thyroid immune-related adverse events (irAEs) in cancer patients treated with PD-1/PD-L1 inhibitors at Tianjin First Central Hospital from January 2020 to March 2023. Thyroid irAEs were characterized as hypothyroidism, hyperthyroidism and thyrotoxicosis followed by hypothyroidism...
January 19, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38240036/ultrastructural-and-immunohistochemical-insights-on-the-anti-glioma-effects-of-a-dual-drug-cocktail-in-an-in%C3%A2-vivo-experimental-model
#36
JOURNAL ARTICLE
Indrani Biswas, Daisy Precilla S, Shreyas S Kuduvalli, Bhavani K, Sivachandran R, Anitha T S
Glioma coined as 'butterfly tumor' exhibits intense heterogeneity at the molecular and cellular levels. Although, Temozolomide exerted a long-ranging and prevailing therapeutic effect against glioma, albeit it has provided modest survival outcome. Fucoidan, (marine brown algal derivative) has demonstrated potent anti-tumor effects including glioma. Nevertheless, there is paucity of studies conducted on Fucoidan to enhance the anti-glioma efficacy of Temozolomide. The present study aimed to explore the plausible synergistic anti-glioma efficacy of Fucoidan in combination with Temozolomide in an in vivo experimental model...
January 19, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38234179/review-of-real-world-experience-with-lurbinectedin-in-relapsed-refractory-small-cell-lung-cancer
#37
REVIEW
Mustafa Wasifuddin, Nosakhare Paul Ilerhunmwuwa, Henry Becerra, Narek Hakobyan, Saad Wasifuddin, Hayder Al Asadi, Jen Chin Wang
Lurbinectedin, a novel antineoplastic agent, was granted the orphan drug designation by the United States Food and Drug Administration (US FDA) and approved for use in relapsed/refractory small cell lung cancer in June 2020. The approval was granted after its efficacy was demonstrated in a multicenter open-label, multi-cohort study enrolling 105 participants. Since then, real-world studies have examined the efficacy and safety profiles of lurbinectedin in clinical practice. By examining these outcomes, this review aims to provide clinicians with the tools necessary to make informed clinical decisions...
January 17, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38189681/a-new-chemotherapy-strategy-for-advanced-hepatocellular-carcinoma-with-exrahepatic-metastasis-predictors-of-long-term-survival
#38
JOURNAL ARTICLE
Juxian Sun, Chang Liu, Dandan He, Dafeng Jiang, Shuqun Cheng, Jie Shi
The prognosis of hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM) is extremely poor. This study aimed to identify prognostic factors for systemic chemotherapy of HCC with EHM. Eighty-five patients who received systemic chemotherapy for HCC with EHM between May 2014 and October 2021 were retrospectively evaluated. Patient demographic data and characteristics of hepatic tumors and EHM were assessed to identify factors that were significantly associated with prognosis. Of the 85 patients, 68 (80...
January 8, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38179685/mechanisms-underlying-dose-limiting-toxicities-of-conventional-chemotherapeutic-agents
#39
REVIEW
Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, Ahmad Reza Dehpour
Dose-limiting toxicities (DLTs) are severe adverse effects that define the maximum tolerated dose of a cancer drug. In addition to the specific mechanisms of each drug, common contributing factors include inflammation, apoptosis, ion imbalances, and tissue-specific enzyme deficiencies. Among various DLTs are bleomycin-induced pulmonary fibrosis, doxorubicin-induced cardiomyopathy, cisplatin-induced nephrotoxicity, methotrexate-induced hepatotoxicity, vincristine-induced neurotoxicity, paclitaxel-induced peripheral neuropathy, and irinotecan, which elicits severe diarrhea...
January 5, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38179655/the-tumor-microenvironment-shaping-cancer-progression-and-treatment-response
#40
REVIEW
Sharav A Desai, Vipul P Patel, Kunal P Bhosle, Sandip D Nagare, Kirti C Thombare
The tumor microenvironment (TME) plays a crucial role in cancer progression and treatment response. It comprises a complex network of stromal cells, immune cells, extracellular matrix, and blood vessels, all of which interact with cancer cells and influence tumor behaviour. This review article provides an in-depth examination of the TME, focusing on stromal cells, blood vessels, signaling molecules, and ECM, along with commonly available therapeutic compounds that target these components. Moreover, we explore the TME as a novel strategy for discovering new anti-tumor drugs...
January 5, 2024: Journal of Chemotherapy
journal
journal
30114
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.